Basel: Trade with Slovenia explodes, the pharmaceutical industry is behind it:
bzbasel.ch/basel/basel-stadt/aussenhandel-novartis-co-gehen-fremd-oder-warum-basel-fuer-slowenien-ploetzlich-so-wichtig-ist-ld.2586028
Story Details
| Last Updated | Mar 01 |
| Total Articles | 1 |
More articles on this subject
Previous
Novartis raises guidance after beating Q1 expectations: Swiss drugmaker Novartis raised its full-year guidance on wider use of psoriasis and arthritis drug ...
reuters.com/business/healthcare-pharmaceuticals/novartis-lifts-fy-guidance-after-q1-results-beat-expectations-2024-04-23/
Quick Glance: Positive Quarterly Results Lead to Guidance Increase at Novartis
- Novartis raises its annual guidance following a successful first quarter.
- Revenue increased by 10% to $11.83 billion, with adjusted operating income growing by 16% to $4.54 billion.
- CEO Vas Narasimhan is focusing more on drug development and has been active in mergers and acquisitions.
- Novartis has secured promising drugs, including an experimental prostate cancer drug from Arvinas and the company MorphoSys, which develops cancer treatments, for 2.7 billion euros.
Job cuts at Novartis and Roche: a blow for the research center: The Swiss pharmaceutical industry is facing a bloodletting. Due to reorganizations at Novartis ...
nzz.ch/wirtschaft/novartis-und-roche-kuendigen-hochqualifizierten-spezialisten-ld.1825752
AHV vote: Now the top earners come to the checkout: Sergio Ermotti and Novartis boss Vas Narasimhan pay over a million francs annually into the AHV ...
tagesanzeiger.ch/ahv-abstimmung-jetzt-kommen-die-spitzenverdiener-an-die-kasse-692829873364
Paid articlePaid
Novartis wants to buy a German cancer drugmaker as it stops recruiting for its own trials
qz.com/norvartis-morphosys-deal-cancer-trials-pause-1851403095
Novartis to cut 680 jobs in product development: Novartis is to cut up to 680 jobs in its development organisation, which helps bring its drugs to market ...
reuters.com/business/world-at-work/novartis-cut-680-jobs-product-development-2024-04-09/
Novartis begins tender offer for cancer-focused MorphoSys: Novartis said on Thursday it has launched a tender offer to acquire MorphoSys ...
reuters.com/business/healthcare-pharmaceuticals/novartis-begins-tender-offer-morphosys-2024-04-11/
CEO pay: can Switzerland compete with the US?: Swiss CEOs are some of the best paid in Europe but compared to peers in the US, their salaries look modest.
swissinfo.ch/eng/multinational-companies/ceo-pay-can-switzerland-compete-with-the-us/73415382
Pharmaceutical company announces job cuts - hundreds of employees in two countries affected
fr.de/wirtschaft/pharmakonzern-kuendigt-stellenabbau-an-hunderte-mitarbeiter-in-zwei-laendern-betroffen-zr-92997399.html
US appeals court revives Regeneron's antitrust lawsuit against Novartis: A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals ...
reuters.com/legal/us-appeals-court-revives-regenerons-antitrust-lawsuit-against-novartis-2024-03-18/
Pharmaceutical industry: Novartis has doubled CEO Narasimhan's compensation: The American received the equivalent of more than 17 million euros in 2023 ...
handelsblatt.com/unternehmen/industrie/pharmabranche-novartis-hat-verguetung-von-konzernchef-narasimhan-verdoppelt/100011818.html
Novartis acquires German biotech MorphoSys for CHF2.5 billion: Even after its numerous acquisitions in 2023, the pharmaceutical company Novartis has not yet ...
swissinfo.ch/eng/business/novartis-acquires-german-biotech-morphosys-for-chf2_5-billion/49189882
Whatever happened to the world’s most expensive drug?: Zolgensma came to the market five years ago with a price tag of $2.1 million. What happened to it?
swissinfo.ch/eng/multinational-companies/whatever-happened-to-the-worlds-most-expensive-drug/75388576
Novartis drops pursuit of Cytokinetics - source: Swiss drugmaker Novartis (NOVN.S) has backed away from its pursuit of Cytokinetics (CYTK.O) ...
reuters.com/business/healthcare-pharmaceuticals/novartis-drops-pursuit-cytokinetics-wsj-2024-01-11/
Novartis signs gene therapy deal with Voyager for $100 mln upfront: Voyager Therapeutics (VYGR.O) said on Tuesday Swiss-based drugmaker Novartis (NOVN ...
reuters.com/business/healthcare-pharmaceuticals/novartis-signs-gene-therapy-deal-with-voyager-100-mln-upfront-2024-01-02/
School desks instead of cars: Will this parking garage one day become a primary school?
bazonline.ch/schulbaenke-statt-autos-wird-dieses-parkhaus-einst-eine-primarschule-785482089106
Novartis misses Q4 net income expectations, extends forecast: Swiss drugmaker Novartis (NOVN.S) reported a 6% gain in fourth-quarter adjusted net income on ...
reuters.com/business/healthcare-pharmaceuticals/novartis-eyes-5-annual-sales-growth-through-2028-2024-01-31/
Quick Glance: South Africa's Goalkeeper Leads Team to Africa Cup of Nations Semi-Finals
- South Africa's Ronwen Williams saves four penalties, securing a spot in the Africa Cup of Nations semi-finals.
- Mothobi Mvala scores decisive penalty in 2-1 shootout win after 0-0 draw, sending South Africa to their first semi-final since 2000.
- Williams makes brilliant saves, carrying South Africa to victory after dominating the early exchanges and surviving several scares.
- South Africa to face Nigeria in semi-final match on Wednesday.
US FDA requires 'boxed warning' for CAR-T cancer therapies: The U.S. health regulator said on Monday companies will be required to add a serious warning on the ...
reuters.com/business/healthcare-pharmaceuticals/us-fda-requires-boxed-warning-car-t-cancer-therapies-2024-01-23/
Biotech Stocks Heat Up, Driven By A Spate Of Billion-Dollar Deals: Biotech stocks heated Thursday as Novartis scooped up a licensing pact with Arvinas and Janux ...
investors.com/news/technology/biotech-stocks-arvinas-novartis-licensing-deal-janux-takeover-interest/
Trend towards frosted facades: Architecture degenerates into a disco ball: The MSG Sphere in Las Vegas and the Novartis Pavilion in Basel reduce the façade to an ...
nzz.ch/feuilleton/trend-zu-mattscheiben-fassaden-architektur-verkommt-zur-discokugel-ld.1777408
Münsterlingen: Novartis pays four million to victims: Between 1940 and 1980, Basel-based pharmaceutical companies carried out drug tests on unknowing patients in ...
nzz.ch/schweiz/muensterlingen-novartis-zahlt-vier-millionen-an-opfer-thurgau-ld.1777071
Novartis in advanced talks to buy Cytokinetics- source: Swiss drugmaker Novartis (NOVN.S) is in the lead to acquire Cytokinetics (CYTK.O) for a deal that could ...
reuters.com/markets/deals/novartis-advanced-talks-buy-cytokinetics-wsj-2024-01-08/
Quick Glance: VW utilizing ChatGPT for driver conversations by mid-year
- Volkswagen integrating ChatGPT to enable driver conversations by mid-year.
- First vehicles with ChatGPT available in North America and Europe from early second quarter.
- AI system capable of recognizing and responding to various demands, such as temperature adjustments and displaying nearby restaurants.
Novartis makes progress with myeloid leukaemia drug: Swiss pharma Novartis sees clinical trial superiority of Scemblix for Philadelphia chromosome-positive ...
swissinfo.ch/eng/sci-tech/novartis-makes-progress-with-myeloid-leukaemia-drug/49109142
FCB CEO Chris Kauffmann in an interview: "We will find the equivalent of Novartis' performance"
bazonline.ch/fcb-ceo-chris-kauffmann-im-interview-wir-finden-das-aequivalent-fuer-die-leistung-von-novartis-824286819910
Paid articlePaid
Inside Vasant 'Vas' Narasimhan's transformation of Novartis, and more
forbesindia.com/article/column/inside-vasant-vas-narasimhans-transformation-of-novartis-and-more/92547/1
Q1/2024 check-up: how the Swiss economy is faring - SWI swissinfo.ch: The highlights of the Swiss economy in the first three months of 2024 - here is our ...
swissinfo.ch/eng/workplace-switzerland/q1-2024-check-up-how-the-swiss-economy-is-faring/75764295
Research: More People Use Mental Health Benefits When They Hear That Colleagues Use Them Too
hbr.org/2024/04/research-more-people-use-mental-health-benefits-when-they-hear-that-colleagues-use-them-too
Pharmaceutical companies: takeovers will reach a record level in 2023: The heavyweights among drug manufacturers took over companies for $110 billion last year ...
nzz.ch/wirtschaft/biotechnologie-ld.1772282
Swiss drug trial victims offered millions in compensation: Some 500 victims of flawed drug tests could be eligible for compensation totaling up to CHF12 ...
swissinfo.ch/eng/sci-tech/swiss-drug-trial-victims-offered-millions-in-compensation/49179934
170 caravans, 220 vehicles: Travellers occupied the site at Novartis and Co.: In the municipality of Huningue near Basel, an illegal settlement with hundreds of ...
bazonline.ch/170-wohnwagen-220-fahrzeuge-fahrende-besetzten-areal-bei-novartis-und-co-703665707706
Paid articlePaid Novartis raises sales growth target to 5% a year through 2027: Novartis (NOVN.S) has dialled up its sales growth target to 5% per year until 2027 ...
reuters.com/business/healthcare-pharmaceuticals/novartis-aims-5-annual-sales-growth-through-2027-2023-11-28/
AstraZenca is betting $2 billion on next-generation cancer treatments: AstraZeneca is acquiring Fusion Pharmaceuticals in a $2-billion deal
qz.com/astrazeneca-fusion-pharmaceuticals-2-billion-acquisitio-1851348307
Paid articlePaid Swiss pharma mega-deal has healthy prognosis: A $440 billion Swiss drug deal may finally have the right formula. Back in 2001 Novartis (NOVN ...
reuters.com/breakingviews/swiss-pharma-mega-deal-has-healthy-prognosis-2023-12-19/
Novartis and Roche: Swiss pharmaceutical duo is looking for a connection: The two Swiss industry giants Roche and Novartis account for around 30 percent of the ...
diepresse.com/17989003/novartis-und-roche-schweizer-pharma-duo-sucht-anschluss
Moderna's new cancer vax, AstraZeneca CEO's big pay, and record-high drug shortages: Pharma news round up
qz.com/moderna-cancer-vax-astrazeneca-ceo-pay-drug-shortages-1851404812
Sports club Novartis in Stein is looking for a landlady for the clubhouse: The new person should have the freedom to decide whether this should become a “real” ...
aargauerzeitung.ch/aargau/fricktal/stein-die-mitglieder-muessen-derzeit-selbst-am-zapfhahn-stehen-der-sportclub-novartis-sucht-wirt-oder-wirtin-fuers-restaurant-ld.2573392
Roche: Competition for Ozempic & Co.: The pharmaceutical company wants to develop “the best drug against obesity,” says Roche boss Thomas Schinecker ...
bazonline.ch/roche-konkurrenz-fuer-ozempic-co-688900380622
Turkey vs. Zolgensma: the battle over the world’s most expensive drug: Turkey and Novartis are in a stand-off over approval of Zolgensma - a $2 ...
swissinfo.ch/eng/multinational-companies/turkey-vs-novartis-the-battle-over-the-worlds-most-expensive-drug/76341423
JB Chemicals buys opthalmology brands from Novartis for Rs 964 crore: JB Chemicals and Pharmaceuticals shall offer employment to the impacted associates working ...
business-standard.com/companies/news/jb-chemicals-buys-opthalmology-brands-from-novartis-for-rs-964-crore-123121901051_1.html
FDA approves medication used to treat asthma for use in people with multiple food allergies
cnn.com/2024/02/16/health/fda-medication-to-help-multiple-food-allergies/
Paid articlePaid
If you can't build the next Ozempic, buy it: Where M&A could be heading in the obesity drug space
cnbc.com/2023/12/13/where-ma-could-be-heading-in-the-obesity-drug-space.html
Paid articlePaid US FDA investigating safety risk of CAR-T cancer therapies: The U.S. Food and Drug Administration (FDA) said on Tuesday it was investigating cancer therapies ...
reuters.com/business/healthcare-pharmaceuticals/us-fda-investigating-safety-risk-car-t-cancer-therapies-2023-11-28/
Top pharma CEO says preparedness for a new pandemic has not improved: Vas Narasimhan, CEO of Novartis, told CNBC that he didn't believe there had been much ...
cnbc.com/2024/01/17/novartis-ceo-says-preparedness-for-a-new-pandemic-has-not-improved.html
Blackstone explores sale of Anthos Therapeutics -sources: Private equity firm Blackstone Inc (BX.N) is exploring the sale of Anthos Therapeutics ...
reuters.com/markets/deals/blackstone-explores-sale-anthos-therapeutics-sources-2023-12-04/
Facing the Challenges: Expert Perspectives on Managing Worsening Heart Failure: How to recognize WHF in patients with HFrEF and improve outcomes? Join as experts ...
ms.spr.ly/6182iL0HK
WSJ News Exclusive | Novartis in Advanced Talks to Buy Cytokinetics: Novartis is close to clinching an acquisition of Cytokinetics and its promising heart drug.
wsj.com/business/deals/novartis-in-advanced-talks-to-buy-cytokinetics-d1032569
Popular weight loss injections: Eli Lilly and Novo Nordisk are chasing records: Investors expect record-high sales from new therapies to treat obesity. However ...
nzz.ch/wirtschaft/beliebte-abnehmspritzen-eli-lilly-und-novo-nordisk-jagen-rekorde-ld.1773336
Novartis AG 2024 Q1 - Results - Earnings Call Presentation: The following slide deck was published by Novartis AG in conjunction with their 2024 Q1 earnings call ...
seekingalpha.com/article/4685255-novartis-ag-2024-q1-results-earnings-call-presentation
Paid articlePaid
USFDA gives nod to Novartis’ therapy for rare cancer among children: The study reported a safety profile consistent with the adult population studied in NETTER-1 ...
financialexpress.com/healthcare/pharma-healthcare/usfda-gives-nod-to-novartis-therapy-for-rare-cancer-among-children/3468162/
Do babies have autism because their mothers took a Novartis drug? - Zofinger Tagblatt
zofingertagblatt.ch/klage-in-den-usa-asthma-mittel-von-novartis-sollte-schwangeren-bei-vorzeitigen-wehen-helfen-doch-hat-es-bei-babys-autismus-ausgeloest/
Novartis’ Multiple Sclerosis drug is effective for up to six years, study reveals
financialexpress.com/healthcare/news-healthcare/novartis-multiple-sclerosis-drug-is-effective-for-up-to-six-years-study-reveals/3462290/
Novartis enters into licensing deal for Arvinas’ cancer drug worth up to $1.01 billion
financialexpress.com/healthcare/pharma-healthcare/novartis-enters-into-licensing-deal-for-arvinas-cancer-drug-worth-up-to-1-01-billion/3454058/
Moderna's new cancer vax, AstraZeneca CEO's big pay, and record-high drug shortages: Pharma news round up
qz.com/moderna-cancer-vax-astrazeneca-ceo-pay-drug-shortages-1851404812
Basel - Novartis is growing faster than expected: The Basel pharmaceutical giant recorded strong growth rates in the first quarter. After the positive start to ...
verlagshaus-jaumann.de/inhalt.basel-novartis-waechst-staerker-als-erwartet.5cdb3a4b-4856-40f7-9e63-ac2af98ebdb3.html
Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results: Beat-and-raise first quarter puts Novartis in a good position for shareholder value ...
seekingalpha.com/article/4685295-novartis-strong-start-beat-and-raise-first-quarter-results
Paid articlePaid Novartis Looks To Get Back On Track With Q1 Earnings: Novartis' key drugs like Fabhalta and Cosentyx may drive short-term growth, offsetting potential losses ...
seekingalpha.com/article/4684711-novartis-looks-to-get-back-on-track-with-q1-earnings
Paid articlePaid
Social enterprises: Good deeds should be countable: To the extent that politics legalizes sustainability, the charitable actions of corporations also change ...
faz.net/aktuell/wirtschaft/unternehmen/dax-konzerne-nachhaltigkeit-soll-zaehlbar-sein-19593345.html
Paid articlePaid
Novartis Seeks Malaria Patients in New Places as Climate Shifts: Malaria season should be over in Burkina Faso and Mali. This year, that’s not the case ...
bloomberg.com/news/articles/2024-04-04/novartis-seeks-malaria-patients-in-new-places-as-climate-shifts
Paid articlePaid Inside Novartis' Outsized Play In India - Forbes India: Forbes India's Manu Balachandran talks about Vasant 'Vas' Narasimhan, CEO, Novartis ...
forbesindia.com/audio/audio/inside-novartis-outsized-play-in-india/92631
Novartis will start doing more fundamental research work in India: Vas Narasimhan
forbesindia.com/article/leadership/novartis-will-start-doing-more-fundamental-research-work-in-india-vas-narasimhan/92613/1
Novartis: Innovating For The World, From India - Forbes India: How Vasant 'Vas' Narasimhan is readying India to play a bigger role in its medicines ...
forbesindia.com/article/leadership/novartis-innovating-for-the-world-from-india/92575/1
Here are Monday's biggest analyst calls: Nvidia, Tesla, Dollar Tree, Mondelez, Teva, Ulta, Carnival & more
cnbc.com/2023/11/27/analysts-are-watching-these-top-stocks-on-monday.html
Paid articlePaid Novartis cuts 440 jobs in Switzerland - Zofinger Tagblatt: Novartis cuts 440 jobs in Switzerland
zofingertagblatt.ch/novartis/
Apontis Pharma: Strong deal with Novartis - Share with price jump: Apontis Pharma cooperates with Novartis, raises forecast for 2024, shares rise by 10%.
deraktionaer.de/artikel/aktien/apontis-pharma-starker-deal-mit-novartis-aktie-mit-kurssprung-20354498.html
Basel - Cartel Office says yes: The pharmaceutical company Novartis is allowed to take over the German company Morphosys.
verlagshaus-jaumann.de/inhalt.basel-kartellamt-sagt-ja.8c6a8759-0819-40ed-8d60-d175c844e136.html
Novartis AG (NVS) Q4 2023 Earnings Call Transcript: Novartis AG (NYSE:NYSE:NVS) Q4 2023 Earnings Conference Call January 31, 2024 8:00 AM ETCompany ...
seekingalpha.com/article/4666409-novartis-ag-nvs-q4-2023-earnings-call-transcript
Sandoz is doing well outside the Novartis group: Sandoz clearly returned to growth last year. Business was particularly good in the USA. At the same time ...
nzz.ch/wirtschaft/sandoz-geglueckter-start-in-die-selbstaendigkeit-dem-generikahersteller-geht-es-ohne-den-perfektionismus-von-novartis-besser-ld.1822046
Paid articlePaid Biotech: Morphosys writes deep red figures before takeover by Novartis: Group loss increased to just under 190 million euros in 2023 from a good 151 million a ...
handelsblatt.com/unternehmen/industrie/biotech-morphosys-schreibt-vor-uebernahme-durch-novartis-tiefrote-zahlen/100023761.html
Roche family shareholders need strong nerves: Roche bought back a large block of shares from Novartis in 2021. This increased the influence of family ...
nzz.ch/wirtschaft/roche-familienaktionaere-brauchen-starke-nerven-ld.1820959
Paid articlePaid In Memorium: Ranjit Shahani: Ranjit Shahani aged 73 passed away on March 9. Industry and well-wishers mourn his sad demise.
financialexpress.com/healthcare/in-memorium-ranjit-shahani/3420412/
3 Top Stocks to Watch From the Best International Money Managers: Managers of highly rated funds own these foreign stocks. Should you?
morningstar.com/stocks/3-top-stocks-watch-best-international-money-managers-2
UK's MHRA revokes authorisation for Novartis' sickle cell drug: Britain's health regulator said on Wednesday it had revoked a conditional marketing authorisation ...
reuters.com/business/healthcare-pharmaceuticals/uks-mhra-revokes-authorisation-novartis-sickle-cell-drug-2024-02-21/
Beyond the Magnificant Seven like NASDAQ's NVIDIA: These European stocks could be worthwhile for investors
finanzen.net/nachricht/aktien/diversifizierung-jenseits-von-nvidia-co-diese-europaeischen-aktien-koennten-sich-fuer-anleger-lohnen-13330156
Egypt’s Health Ministry, Novartis sign protocol to modernise cardiac catheterisation system - Dailynewsegypt
dailynewsegypt.com/2024/02/26/egypts-health-ministry-novartis-sign-protocol-to-modernise-cardiac-catheterisation-system/
Who was Ranjit Shahani: A titan in India's pharmaceutical, business landscape. Know his contributions and more | Mint
livemint.com/companies/people/who-was-ranjit-shahani-a-titan-in-indias-pharmaceutical-business-landscape-know-his-contributions-and-more-11709973943106.html
Former Vice Chairman of Novartis India Ranjit Shahani passes away | Mint: Ranjit Shahani, former Vice Chairman and Managing Director of Novartis India and ...
livemint.com/news/india/vice-chairman-novartis-india-ranjit-shahani-passes-away-jb-pharmaceuticals-news-death-11709972334774.html
Reduce the exits: Of late, however, there have been several instances of MNCs quitting India or scaling down their stake in their India subsidiaries.
financialexpress.com/opinion/reduce-the-exits/3403815/
New medicine is needed: The pharmaceutical industry is looking for the next cash cow
faz.net/aktuell/wirtschaft/unternehmen/novartis-offerte-fuer-morphosys-die-pharmabranche-sucht-den-naechsten-goldesel-19500881.html
Paid articlePaid Novartis signs gene therapy deal with Voyager for $100 mln upfront: Voyager Therapeutics (VYGR.O) said on Tuesday Swiss-based drugmaker Novartis (NOVN ...
reuters.com/business/healthcare-pharmaceuticals/novartis-signs-gene-therapy-deal-with-voyager-100-mln-upfront-2024-01-02/
Quick Glance: Over 100 Killed in 'Terrorist Attacks' near Tomb of Iranian Guards' Soleimani
- Two explosions at ceremony in Kerman, Iran, kill over 100 and injure many more.
- Iranian officials blame unspecified 'terrorists' for remotely detonated explosive attacks.
- At least 103 dead and 211 injured; one of the worst attacks in Iran.
- Cemetery evacuated and closed; Iran threatens strong response to the crimes.
Next
New to NewsWall?
Sign up now to get your own personalized news!
Trending topics